Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
FGC-H5225 | Human | Human FGF R2 (IIIc) protein, His Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
Immobilized Human FGFR2 (IIIc), His Tag (Cat. No. FGC-H5225) at 5 μg/mL (100 μL/well) can bind Biotinylated Human FGF basic, Tag Free with a linear range of 0.04-1.25 μg/mL (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Erdafitinib | G-024; JNJ-493; 890E37NHMV; JNJ-42756493 | Approved | Balversa | United States | Carcinoma, Transitional Cell | Janssen Biotech Inc | 2019-04-12 | Solid tumours; Carcinoma; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Bile Duct Neoplasms; Urologic Neoplasms; Hepatic Insufficiency; Lymphoma; Carcinoma, Hepatocellular; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung | Details | |
Pemigatinib | INCB-054828; IBI-375; INCB-54828; BH-009 | Approved | Incyte Corp | Pemazyre, 伯坦, 达伯坦 | Hong Kong | Biliary Tract Neoplasms | Innovent Biologics(Suzhou) Co Ltd | 2020-04-17 | Biliary Tract Neoplasms; Solid tumours; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Translocation, Genetic; Bile Duct Neoplasms; Endometrial Neoplasms | Details |
Regorafenib | DAST; BAY-73-4506 | Approved | Bayer Ag | Resihance, Stivarga | Mainland China | Gastrointestinal Stromal Tumors | Bayer Pharma Ag | 2012-09-27 | Solid tumours; Carcinoma, Renal Cell; Rectal Neoplasms; Colonic Neoplasms; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms | Details |
Lenvatinib Mesylate | MK-7902; ER-203492-00; E-7080 | Approved | Eisai Co Ltd | Kisplyx, Lenvima, Lenvima/Kisplyx, 乐卫玛 | Japan | Endometrial Neoplasms | Eisai Co Ltd | 2015-02-13 | Liver Diseases; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular; Lymphoma; Thyroid Neoplasms; Endometrial Neoplasms; Hepatic Insufficiency; Sarcoma; Urinary Bladder Neoplasms; Solid tumours; Adenocarcinoma of Lung; Thyroid Carcinoma, Anaplastic; Kidney Diseases; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Renal Insufficiency; Carcinoma, Renal Cell; Liver Neoplasms; Biliary Tract Neoplasms | Details |
Nintedanib Esylate | BIBF-1120 | Approved | C.H. Boehringer Sohn Ag & Co. Kg | Ofev, Vargatef | Mainland China | Idiopathic Pulmonary Fibrosis | Boehringer Ingelheim International Gmbh | 2014-10-15 | Ovarian Neoplasms; Solid tumours; Carcinoma, Renal Cell; Scleroderma, Systemic; Idiopathic Pulmonary Fibrosis; Lung Diseases, Interstitial; Pulmonary Fibrosis; Multiple Myeloma; Prostatic Neoplasms; Peritoneal Neoplasms; Hepatic Insufficiency; Genital Neoplasms, Female; Colorectal Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
Anlotinib Dihydrochloride | AL-3818 | Approved | Advenchen Laboratories, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 福可维 | Mainland China | Small Cell Lung Carcinoma | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 2018-05-08 | Endometrial Neoplasms; Cholangiocarcinoma; Nasopharyngeal Carcinoma; Urologic Neoplasms; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Bone Neoplasms; Sarcoma, Alveolar Soft Part; Gallbladder Neoplasms; Medullary thyroid cancer (MTC); Thyroid Neoplasms; Esophageal Squamous Cell Carcinoma; Lung Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Osteoma; Carcinoma, Renal Cell; Head and Neck Neoplasms; Solid tumours; Biliary Tract Neoplasms; Ovarian Neoplasms; Thoracic Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Genital Diseases, Female; Leiomyosarcoma; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Lymphoma, Large B-Cell, Diffuse; Sarcoma, Synovial; Neuroendocrine Tumors; Sarcoma; Bile Duct Diseases | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Aprutumab ixadotin | BAY-1187982 | Phase 1 Clinical | Bayer Ag | Neoplasms | Details |
Lucitanib | AL-3810; CO-3810; S-80881 | Phase 3 Clinical | Advenchen Laboratories Nanjing Ltd | Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Breast Neoplasms; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Thymus Neoplasms; Genital Neoplasms, Female; Carcinoma, Small Cell; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
Aprutumab | FGFR-moAb; FGFR2-TTC; BAY-1179470 | Phase 1 Clinical | Bayer Ag | Neoplasms | Details |
TT-00434 | TT-00434 | Phase 1 Clinical | Yaojie Ankang (Nanjing) Technology Co Ltd | Solid tumours; Urinary Bladder Neoplasms | Details |
S-49076 | S-49076 | Phase 2 Clinical | Servier | Glioblastoma; Carcinoma, Non-Small-Cell Lung | Details |
CH-5183284 | FF-284; CH-5183284; Debio-1347 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours; Breast Neoplasms | Details |
BPI-17509 | BPI-17509 | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Solid tumours | Details |
Sprifermin | zFGF-5; Zfgf5; AS-902330; rhFGF-18; trFGF-18; FGF-18 | Phase 2 Clinical | Zymogenetics | Cartilage Diseases; Knee Injuries; Osteoarthritis, Knee; Osteoarthritis | Details |
Alofanib | RPT-835 | Phase 1 Clinical | Russian Pharmaceutical Technologies Llc | Stomach Neoplasms | Details |
PRN-1371 | PRN-1371 | Phase 1 Clinical | Principia Biopharma Inc | Solid tumours; Urinary Bladder Neoplasms | Details |
RLY-4008 | RLY-4008 | Phase 1 Clinical | Relay Therapeutics Inc | Solid tumours; Stomach Neoplasms; Breast Neoplasms; Translocation, Genetic; Cholangiocarcinoma; Endometrial Neoplasms | Details |
Gunagratinib | ICP-192 | Phase 2 Clinical | Beijing Tiancheng Pharmaceutical Technology Co Ltd | Biliary Tract Neoplasms; Solid tumours; Stomach Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Cholangiocarcinoma; Lung Neoplasms | Details |
AZD-4547 | AZD-4547; ABSK-091; AZD4547; ABSK091 | Phase 2 Clinical | Astrazeneca Plc | Solid tumours; Gastrointestinal Diseases; Stomach Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Breast Neoplasms | Details |
HMPL-453 | HMPL-453 | Phase 2 Clinical | Hutchison Huangpu Medicine (Shanghai) Co Ltd | Biliary Tract Neoplasms; Solid tumours; Neoplasms, Mesothelial; Mesothelioma; Bile Duct Neoplasms | Details |
HH185 | 3-D185; HH-185; 3D185; 3D-185 | Phase 1 Clinical | Shanghai Medicilon Inc, ShangHai HaiHe Biopharma Co Ltd, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Solid tumours | Details |
E-7090 | E-7090 | Phase 2 Clinical | Eisai Co Ltd | Biliary Tract Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Hepatic Insufficiency | Details |
Bemarituzumab | FPA-144 | Phase 3 Clinical | Five Prime Therapeutics | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Adenocarcinoma; Gastrointestinal Neoplasms | Details |
Futibatinib | TAS-120 | Phase 3 Clinical | Otsuka Pharmaceutical Co Ltd, Taiho Pharmaceutical Co Ltd | Bone Marrow Neoplasms; Solid tumours; Stomach Neoplasms; Carcinoma; Esophageal Neoplasms; Carcinoma, Transitional Cell; Central Nervous System Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Lymphoma; Carcinoma, Non-Small-Cell Lung | Details |
This web search service is supported by Google Inc.